Background Digital mobility outcomes (DMOs) have been cited as potential clinical endpoints for trials in Parkinson's disease (PD). Current evidence from the Mobilise-D consortium suggests that selected DMOs are technically valid, with emerging research on their clinical validity. However, regulatory qualification of D...
Jack Lumsdon, Ríona Mc Ardle, Megan Hanrahan et al.· Journal of Parkinson's Disea...· 0 citations
Abstract Step-width variation and foot-placement are relevant measures for Parkinson-related gait assessment, but are difficult to derive robustly from compact wearable sensor setups. Previous work within the same project used bodyworn magnetoelectric sensors to estimate step width from relative distance measurements,...
H. Eikens, J. Welzel, C. Hansen et al.· Current Directions in Biomed...· 0 citations
Cognitive aging is shaped by genetic variation, environmental factors, and health-related conditions. Until now, it is largely unclear why some individuals maintain their cognitive function, and others show progressive cognitive decline. This study uncovered determinants of distinct cognitive aging trajectories in the...
L. Federmann, Christian Mychajliw, U. Suenkel et al.· GeroScience· 0 citations
Smartphone-based digital biomarkers offer a promising approach to improving diagnostic accuracy in PD and are emerging as a frontier in precision neurology and scalable PD care, however, these findings have several limitations and should be interpreted with caution.
O. Phokaewvarangkul, Suppakorn Yamutai, R. Bhidayasiri et al.· Journal of neural transmissi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.